Reports Q3 revenue $151.7M, consensus $158.63M. Cash and cash equivalents were $398.2M as of September 30. “Our results this quarter fell short of our expectations given greater-than-anticipated disruption from the sales restructuring we implemented in the quarter and cautious customer spending. As these dynamics persist, especially under a difficult macro backdrop, our revenue growth this year will be lower than our previous expectations,” said Serge Saxonov, Co-founder and CEO of 10x Genomics (TXG). “Despite these challenges, I am confident that the steps we are taking will enable us to reach more customers, execute consistently across the portfolio and drive the broad democratization of our technologies to reach the full potential of the large opportunity ahead.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TXG:
- TXG Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- PacBio includes Onso platform in 10x Genomics Compatible Partner Program
- UPC rules in favor of Bruker and NanoString invalidating 10x Genomics patent
- 10x Genomics price target lowered to $21 from $24 at Barclays
- Cathie Wood’s ARK Investment buys 1.15M shares of 10x Genomics today